Role of the renin-angiotensin system in cardiovascular disease

Cardiovascular Drugs and Therapy

Volumn 24, Issue 4, 2010, Pages 341-344

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRIC OXIDE; RENIN INHIBITOR; VALSARTAN;

ACUTE HEART INFARCTION; AGING; ARTERIAL WALL THICKENING; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; HYPERTENSION; MORTALITY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 78149361910     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-010-6230-3     Document Type: Conference Paper

References (36)

1. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-6.
2. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89(suppl): 3A-10.
3. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients-a meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
4. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation. 2003;107:139-46. (Pubitemid 36070946)
5. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res. 1991;68:1560-8.
6. Ferrario CM, Strawn WB. Role of the renin-angiotensinaldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121-8.
7. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals. Arterioscler Thromb Vasc Biol. 2006;26:826-32.
8. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept. 2000;93:65-77.
9. Thurmann PA, Kenedi P, Schmidt A, et al. Influence of the Angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998;98:2037-42.
10. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10:1-8.
11. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group: Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87: VI-40-48.
12. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25:292-9.
13. Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583-91.
14. Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, Levy D, et al. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J. 2007;28:2644-52. (Pubitemid 350071528)
15. Francis GS, Benedict C, Johnston DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation. 1990;82:1724-9.
16. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. The Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction: Results of the survival and ventricular enlargement (SAVE) trial. N Engl J Med. 1992;327:669-77.
17. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-8.
18. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-convertingenzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-6.
19. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
20. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-10.
21. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53 [HOPE].
22. Sealey JE, Gerten-Banes J, Laragh JH. The renin system: variations in man measured by radioimmunoassay and bio-assay. Kidney Intl. 1972;1:240-53.
23. Nussberger J, Waeber B, Brunner HR. Plasma angiotensin II and the antihypertensive action of angiotensin-converting enzyme inhibition. Am J Hypertens. 1989;2:286-93. (Pubitemid 19087207)
24. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail. 2004;6(7):937-45.
25. Campbell DJ, Aggarwal A, Esler M, et al. β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet. 2001;358:1609-10.
26. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect on carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-8 [COPERNICUS]. (Pubitemid 32479962)
27. Merit-HF Study Group. Effect of metroprolol CR/XL in chronic heart failure: metroprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
28. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
29. McMurray JJ, Pitt B, Latini R, Maggioni P, Solomon SD, Keefe DL, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
30. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221-9.
31. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
32. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
33. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. J Am Coll Cardiol. 2004;43:2022-7.
34. Cohn JN, Tognoni G. for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.
35. Julius S, Nesbitt SD, Egan BM, for the Trial of Preventing Hypertension (TROPHY) Study Investigators, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-97.
36. Duprez DA, Florea ND, Jones K, Cohn JN. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: The DETECTIV Pilot Study. J Am Coll Cardiol. 2007;50:835-9.